Intensified Viral Vector Manufacturing Using KrosFlo® TFDF® Tangential Flow Depth Filtration System

By Riaj Mahamud, Ly Truong, Marlon Tannous, Westley Blacklock, Philip Yuen, Mike Bransby, René Gantier, and Keen Chung, Repligen

To meet the rapidly increasing global demand for viral vectors used in gene therapy, substantial improvements in manufacturing productivity are essential. We implemented an integrated perfusion-based bioprocessing strategy that utilizes the KrosFlo® TFDF® (Tangential Flow Depth Filtration) system to intensify both cell growth and viral vector production. This approach enabled a significant enhancement in upstream processing efficiency. Specifically, by applying perfusion prior to transfection, we achieved a threefold increase in cell density at the point of transfection—approximately 9 million cells per milliliter—compared to the traditional batch process, which typically reaches only about 3 million cells per milliliter.

Explore how this approach offers a promising path forward for meeting the growing needs of the gene therapy industry and unlocking its full therapeutic potential.